Posted by Michael Wonder on 22 Nov 2019
Aerie Pharmaceuticals receives European Commission approval for Rhokiinsa (netarsudil 0.02% ophthalmic solution)
21 November 2019 - Aerie Pharmaceuticals today announced the European Commission has granted a marketing authorisation for Rhokiinsa (netarsudil 0.02% ophthalmic solution) for the reduction of elevated intra-ocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.
The marketing authorisation application for Rhokiinsa was accepted for review by the EMA in October 2018. Aerie received a positive scientific opinion recommending approval of the Rhokiinsa application from the EMA’s CHMP in September 2019.
